Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy
eJHaem · 2023-02 · 4 (1) · 216-220
DOI: 10.1002/jha2.639 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 20.01.2023. Verfasst von Thi H O Nguyen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeiGene.
Abstract (Originalsprache)
Zanubrutinib‐treated and treatment‐naïve patients with chronic lymphocytic leukaemia (CLL) or Waldenstrom's macroglobulinaemia were recruited in this prospective study to comprehensively profile humoral and cellular immune responses to COVID‐19 vaccination. Overall, 45 patients (median 72 years old) were recruited; the majority were male (71%), had CLL (76%) and were on zanubrutinib (78%). Seroconversion rates were 65% and 77% following two and three doses, respectively. CD4 + and CD8 + T‐cell response rates increased with third dose. In zanubrutinib‐treated patients, 86% developed either a humoral or cellular response. Patients on zanubrutinib developed substantial immune responses following two COVID‐19 vaccine doses, which further improved following a third dose.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Microbiology and Immunology University of Melbourne Parkville Victoria Australia.
- Department of Infectious Diseases Peter MacCallum Cancer Centre Melbourne Victoria Australia.
- Department of Haematology St Vincent's Hospital Fitzroy Victoria Australia.
- Department of Clinical Haematology Peter MacCallum Cancer Centre and Royal Melbourne Hospital Melbourne Victoria Australia.
- ARC Centre of Excellence in Convergent Bio-Nano Science and Technology University of Melbourne Melbourne Victoria Australia.
- Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School Monash University Melbourne Victoria Australia.
ORCID-Profile: Chhay Lim, Constantine S Tam, Benjamin W Teh
Förderung
- BeiGene
Zitieren
APA
Nguyen, T. H. O., Lim, C., Lasica, M., Whitechurch, A., Tennakoon, S., Saunders, N. R., Allen, L. F., Rowntree, L. C., Chua, B. Y., Kedzierski, L., Tan, H. X., Wheatley, A. K., Kent, S. J., Karapanagiotidis, T., Nicholson, S., Williamson, D. A., Slavin, M. A., Tam, C. S., Kedzierska, K., & Teh, B. W. (2023). Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy. eJHaem, 4(1), 216-220. https://doi.org/10.1002/jha2.639
Vancouver
Nguyen THO, Lim C, Lasica M, Whitechurch A, Tennakoon S, Saunders NR, et al. Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy. eJHaem. 2023;4(1):216-220. doi:10.1002/jha2.639
BibTeX
@article{Nguyen2023,
author = {Nguyen, Thi H O and Lim, Chhay and Lasica, Masa and Whitechurch, Ashley and Tennakoon, Surekha and Saunders, Natalie R and Allen, Lilith F and Rowntree, Louise C and Chua, Brendon Y and Kedzierski, Lukasz and Tan, Hyon-Xhi and Wheatley, Adam K and Kent, Stephen J and Karapanagiotidis, Theo and Nicholson, Suellen and Williamson, Deborah A and Slavin, Monica A and Tam, Constantine S and Kedzierska, Katherine and Teh, Benjamin W},
title = {Prospective comprehensive profiling of immune responses to COVID‐19 vaccination in patients on zanubrutinib therapy},
journal = {eJHaem},
year = {2023},
volume = {4},
number = {1},
pages = {216--220},
doi = {10.1002/jha2.639}
}
EUVIMED